Metall Zug AG Class B · SIX:METN
Metall Zug AG Class B — H1 2024 Earnings Presentation
36 slides from Metall Zug AG Class B's earnings presentation, Aug 20, 2024
Slide 1: Metall Zug AG - Welcome
METALL ZUG AG - WELCOME Investor Presentation – August 20, 2024 Matthias Rey, CEO Urs Scherrer, CFO Bettine Killmer, Head of Corporate Communications & IR Investor Presentation - August 20, 2024 1
Slide 2: Content
METALL ZUG GROUP CONTENT 1. Group Financial Report HY 1/2024 2. Business Units − Infection Control − Joint venture with Miele − Medical Devices − Others − Technologycluster & Infrastructure 3. Sustainability @ Metall Zug 4. Metall Zug Group – Outlook 2024 5. Information for Investors Investor Presen
Slide 3: Group Financial Report HY 1/2024
GROUP FINANCIAL REPORT HY 1/2024
Slide 4: Overview HY 1/2024
METALL ZUG GROUP OVERVIEW HY 1/2024 – Group net sales of CHF 181.2 million (HY 1/23: CHF 228.4 million), organic sales decrease -10.6% – Divestment effect Belimed Infection Control and Belimed Life Science of CHF -19.9 million (-8.7%) – Negative FX effect of CHF –3.1 million (-1.4%) – Infection Cont
Slide 5: Income Statement
GROUP FINANCIAL REPORT INCOME STATEMENT CHF million HY 1/24 in % HY 1/23 in % Comment restated* Net sales 181.2 100.0 228.4 100.0 Cost of Goods and Services sold -123.2 -68.0 -152.3 -66.7 Gross profit 57.9 32.0 76.1 33.3 Maketing and sales expenses -26.7 -14.7 -28.0 -12.2 Research and development ex
Slide 6: Associated Companies
GROUP FINANCIAL REPORT ASSOCIATED COMPANIES In CHF million HY 1/24 V-ZUG Komax SteelcoBelimed Others Total Pro rata net result 2.6 0.6 -0.6 -0.4 2.2 Adjustment to previous year's actual result -0.8 -3.3 n/a 0.0 -4.1 Total result 1.8 -2.7 -0.6 -0.4 -1.9 HY 1/23 V-ZUG Komax SteelcoBelimed Others Total
Slide 7: Net Sales HY 1/24
GROUP FINANCIAL REPORT NET SALES HY 1/24 by Business Unit by region Others Asia/Pacific/Others 18% 13% Switzerland (21%) (17%) 15% (15%) Technologycluster & Medical Devices Infrastructure 45% 0% (41%) (0%) Americas Europe w/o 39% Switzerland (38%) 33% Infection Control (30%) 37% (38%) (Previous year
Slide 8: Net Sales Analysis
GROUP FINANCIAL REPORT NET SALES ANALYSIS ORGANIC GROWTH EXTERNAL FX GROUP REPORTED Net sales in CHF million Investor Presentation - August 20, 2024 8
Slide 9: Operating Result (EBIT) Analysis
GROUP FINANCIAL REPORT OPERATING RESULT (EBIT) ANALYSIS OPERATIONAL (BUs) GROUP REPORTED EBIT in CHF million Investor Presentation - August 20, 2024 9
Slide 10: Balance Sheet
GROUP FINANCIAL REPORT BALANCE SHEET CHF million 06/30/2024 in % 12/31/2023 in % Comment restated* Cash and cash equivalents / securities 17.2 2.8 29.8 4.3 Other current assets 116.3 18.8 206.9 30.0 Current assets 133.5 21.6 236.7 34.4 Tangible assets 156.9 25.4 169.6 24.6 Includes participation (eq
Slide 11: Cash Flow Statement
GROUP FINANCIAL REPORT CASH FLOW STATEMENT CHF million HY 1/24 HY 1/23 Comment restated* Cash flow from operating activities 6.7 6.9 Cash flow from investing activities -18.6 -7.8 - of which investments in tangible assets -14.1 -21.2 - of which investments in intangible assets -0.7 -0.2 HY 1/24: dis
Slide 12: Business Units
NG _ azz METALL ZUG BUSINESS UNITS
Slide 13: Infection Control
INFECTION CONTROL HY 1/24: NET SALES CHF 68.7 MILLION; EBIT CHF -3.9 MILLION Investor Presentation - August 20, 2024 13
Slide 14: Infection Control: Key Figures and Overview
INFECTION CONTROL KEY FIGURES AND OVERVIEW CHF million HY 1/24 HY 1/23 Δ Net Sales by region 4% 15% Net sales 68.7 1) 88.5 -22.4% (23%) (7%) Operating result (EBIT) -3.9 -4.4 2) 11.9% Switzerland EBIT margin in % -5.7 -5.0 -70bp Europe (excl. CH) 1) For the consolidation period from January 1, 2024
Slide 15: Update Joint Venture with Miele – SteelcoBelimed
UPDATE JOINT VENTURE WITH MIELE – STEELCOBELIMED – Respective relevant authorities granted merger clearance for joint venture between Metall Zug and Miele – Transaction was closed on June 7, 2024. Metall Zug has contributed its Infection Control Business Unit and the Belimed Life Science Group, and
Slide 16: Medical Devices
MEDICAL DEVICES HY 1/24: NET SALES CHF 81.6 MILLION; EBIT CHF 2.4 MILLION Investor Presentation - August 20, 2024 16
Slide 17: Medical Devices: Key Figures and Overview
MEDICAL DEVICES KEY FIGURES AND OVERVIEW CHF million HY 1/24 HY 1/23 Δ Net Sales by region 16% 5% Net sales 81.6 93.9 -13.1% (18%) (5%) Operating result (EBIT) 2.4 12.6 -81.3% Switzerland EBIT margin in % 2.9 13.4 -1050bp Europe (excl. CH) Americas Asia / Pazific / Others 38% – Higher order intake i
Slide 18: Medical Devices: Strategic Priorities
MEDICAL DEVICES STRATEGIC PRIORITIES – Focus on ophthalmology – Complementing and expanding solution portfolio including digitalization, artificial intelligence and data processing – Expanding training portfolio by increasing simulation and training opportunities for ophthalmologists, ophthalmic sur
Slide 19: Others: Belimed Life Science, Gehrig Group
OTHERS: BELIMED LIFE SCIENCE, GEHRIG GROUP, METALL ZUG AG (CORPORATE) HY 1/24 : NET SALES CHF 32.8 MILLION; EBIT CHF 60.2 MILLION Investor Presentation - August 20, 2024 19
Slide 20: Others: Key Figures and Overview
OTHERS KEY FIGURES AND OVERVIEW CHF million HY 1/24 HY 1/23 Δ Net sales 32.8 1) 50.1 -34.6% Operating result (EBIT) 60.2 2) -2.1 n/a EBIT margin in % 183.5 -4.1 18760bp 1) Net sales of Belimed Life Science for the consolidaion period from January 1, 2024 until June 7, 2024 2) Includes book gain from
Slide 21: Technologycluster & Infrastructure
TECHNOLOGYCLUSTER & INFRASTRUCTURE HY 1/24 : NET SALES CHF 0.1 MILLION; EBIT CHF 1.7 MILLION Tech Cluster Zug Grienbachstrasse 11 Mobility Hub Pi CHF million HY 1/24 HY 1/23 Δ Net sales 0.1 0.0 n/a Operating result (EBIT) 1.7 0.8 120.9% EBIT margin in % n/a n/a n/a Investor Presentation - August 20,
Slide 22: Tech Cluster Zug – Significant Development Potential
TECHNOLOGYCLUSTER & INFRASTRUCTURE TECH CLUSTER ZUG – SIGNIFICANT DEVELOPMENT POTENTIAL Current projects Total area potential - Development area (ground): approx. 46’200 m2 refActory + Grienbachstrasse (5’200 m2) + MHZN (6’500 m2) + Project Pi (2’700 m2) = Total: 60’600 m2 - Building volume TCZ: Up
Slide 23: Tech Cluster Zug – Major Rental Projects
TECHNOLOGYCLUSTER & INFRASTRUCTURE TECH CLUSTER ZUG – MAJOR RENTAL PROJECTS SHL Südtor refActory 102’632 m3 building volume 42’300 m3 building volume 11’140 m2 production area 45 parking lots Project size 5’100 m2 office space 80 parking lots Showroom and museum V-ZUG, canteen, Usage Combined produc
Slide 24: Tech Cluster Zug / Others – Major Sales Projects
TECHNOLOGYCLUSTER & INFRASTRUCTURE TECH CLUSTER ZUG / OTHERS – MAJOR SALES PROJECTS CreaTower I Project Pi (not part of TCZ development plan area) 35’696 m3 building volume 95’195 m3 building volume 892 m2 ground to be sold Approx. 16’500 m2 living space Project size 6’863 m2 office space (One of th
Slide 25: Investments in Real Estate Development Projects
TECHNOLOGYCLUSTER & INFRASTRUCTURE INVESTMENTS IN REAL ESTATE DEVELOPMENT PROJECTS CAPEX of major TCZ rental projects / rental income In the current environment, Metall Zug is CHF million (Mobility Hub Zug Nord, Westhive, SHL Südtor & refActory) aiming for a net return of around 3% also taking into
Slide 26: Sustainability @ MZ
NG _ azz METALL ZUG SUSTAINABILITY @ MZ
Slide 27: Greenhouse Gas Fund (GHG)
SUSTAINABILITY GREENHOUSE GAS FUND (GHG) – Since 2018 Metall Zug charges an internal levy of CHF 120 per ton of CO2 for the benefit of the GHG from BUs → additional incentive to reduce CO2 emissions – Resources from the fund provide substantial financial support to the companies of the Metall Zug Gr
Slide 28: Greenhouse Gas Fund
SUSTAINABILITY GREENHOUSE GAS FUND Projects sponsored (inter alia): – Circular economy at Haag-Streit for slit lamps (refurbishment, re-manufacturing) – Circular economy at Gehrig Group for professional dishwashers (material optimization, collaboration with suppliers, 'All inclusive rent' model) – A
Slide 29: Greenhouse Gas Fund
SUSTAINABILITY GREENHOUSE GAS FUND Projects sponsored (inter alia): – Energy efficiency on product level at Belimed Infection Control (Electro Hydro Dynamic Air Amplifier, remote diagnosis, firmware-update over the air) – Energy efficiency and pollution prevention at Belimed Life Science (innovative
Slide 30: Metall Zug Group 2024
NG _ azz METALL ZUG METALL ZUG GROUP 2024
Slide 31: What We Planned for 2024 and What We Achieved in HY 1
METALL ZUG GROUP WHAT WE PLANNED FOR 2024 AND WHAT WE ACHIEVED IN HY 1 − Increase sales with a focus on US and Asian markets − Review the implementation of strategic initiatives − R&D push: Further development of microscopy (analogue and digital), digitalization of devices and product updates − Succ
Slide 32: Outlook FY 2024
METALL ZUG GROUP OUTLOOK FY 2024 − Economical and political uncertainties → no detailed guidance for FY 2024 possible − Order intake in the Medical Devices Business Unit increased slightly in HY 1/24 compared to HY 1/23 → slight increase in sales can be expected for HY 2/24 − Continuing high cost ba
Slide 33: Information for Investors
Me _ azz METALL ZUG INFORMATION FOR INVESTORS
Slide 34: Financial Calendar
METALL ZUG GROUP FINANCIAL CALENDAR March 25, 2025 Publication of Annual Report / Earnings Call May 9, 2025 Ordinary Annual General Meeting of Shareholders 2025 August 25, 2025 Publication of Half-year Report 2025 Investor Presentation - August 20, 2024 34
Slide 35: Contact
METALL ZUG GROUP CONTACT Urs Scherrer CFO Bettine Killmer Head of Corporate Communications & Investor Relations Metall Zug AG Industriestrasse 66 (postal address), Grienbachstrasse 11 (office address) 6302 Zug Switzerland Phone: +41 58 768 60 50 Investor Presentation - August 20, 2024 35
Slide 36: Disclaimer
METALL ZUG GROUP DISCLAIMER Metall Zug AG has made great efforts to include accurate and up-to-date information in this document. However, we make no representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this document and disclaim any